- Home
- CANF vs GSUN Comparison
CANF vs GSUN Comparison
Compare CANF & GSUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- GSUN
- Stock Information
- Founded
- CANF 1994
- GSUN 1997
- Country
- CANF Israel
- GSUN China
- Employees
- CANF N/A
- GSUN N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- GSUN Other Consumer Services
- Sector
- CANF Health Care
- GSUN Real Estate
- Exchange
- CANF Nasdaq
- GSUN Nasdaq
- Market Cap
- CANF 14.4M
- GSUN 5.6M
- IPO Year
- CANF N/A
- GSUN 2022
- Fundamental
- Price
- CANF $1.48
- GSUN $2.71
- Analyst Decision
- CANF Strong Buy
- GSUN
- Analyst Count
- CANF 2
- GSUN 0
- Target Price
- CANF $14.00
- GSUN N/A
- AVG Volume (30 Days)
- CANF 1.2M
- GSUN 15.1K
- Earning Date
- CANF 12-31-2024
- GSUN 02-05-2025
- Dividend Yield
- CANF N/A
- GSUN N/A
- EPS Growth
- CANF N/A
- GSUN N/A
- EPS
- CANF N/A
- GSUN N/A
- Revenue
- CANF $667,000.00
- GSUN $6,336,931.00
- Revenue This Year
- CANF $409.56
- GSUN N/A
- Revenue Next Year
- CANF N/A
- GSUN N/A
- P/E Ratio
- CANF N/A
- GSUN N/A
- Revenue Growth
- CANF N/A
- GSUN N/A
- 52 Week Low
- CANF $1.29
- GSUN $2.21
- 52 Week High
- CANF $4.69
- GSUN $11.20
- Technical
- Relative Strength Index (RSI)
- CANF 35.58
- GSUN 42.09
- Support Level
- CANF $1.30
- GSUN $2.71
- Resistance Level
- CANF $1.72
- GSUN $2.89
- Average True Range (ATR)
- CANF 0.18
- GSUN 0.19
- MACD
- CANF -0.01
- GSUN 0.01
- Stochastic Oscillator
- CANF 17.92
- GSUN 6.85
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About GSUN Golden Sun Education Group Limited
Golden Sun Health Technology Group Ltd is engaged in the provision of education and management services in the People's Republic of China. It offers tutorial centers for children and adults, one educational company that partners with high schools to offer language classes to their students, and one logistics company that provides logistic and consulting services. The company operates in two segments; Education segment and the Wellness segment. Majority of the revenue is generated from the Education segment which offers foreign language tutorial services and other education training management services in China. The wellness segment offers wellness service and related products.